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Genome-wide association study identifies multiple
susceptibility loci for multiple myeloma
Jonathan S. Mitchell1,*, Ni Li1,*, Niels Weinhold2,3,*, Asta Fo¨rsti4,5,*, Mina Ali6,*, Mark van Duin7,*,
Gudmar Thorleifsson8, David C. Johnson9, Bowang Chen4, Britt-Marie Halvarsson6, Daniel F. Gudbjartsson8,10,
Rowan Kuiper7, Owen W. Stephens2, Uta Bertsch3,11, Peter Broderick1, Chiara Campo4, Hermann Einsele12,
Walter A. Gregory13, Urban Gullberg6, Marc Henrion1, Jens Hillengass3, Per Hoffmann14,15, Graham H. Jackson16,
Ellinor Johnsson6, Magnus Jo¨ud6,17, Sigurjur Y. Kristinsson18, Stig Lenhoff19, Oleg Lenive1, Ulf-Henrik Mellqvist20,
Gabriele Migliorini1, Hareth Nahi21, Sven Nelander22, Jolanta Nickel3, Markus M. No¨then14,23, Thorunn Rafnar8,
Fiona M. Ross24, Miguel Inacio da Silva Filho4, Bhairavi Swaminathan6, Hauke Thomsen4, Ingemar Turesson19,
Annette Vangsted25, Ulla Vogel26, Anders Waage27, Brian A. Walker2, Anna-Karin Wihlborg6, Annemiek Broyl7,
Faith E. Davies2, Unnur Thorsteinsdottir8,28, Christian Langer29, Markus Hansson6,19, Martin Kaiser9,
Pieter Sonneveld7, Kari Stefansson8,**, Gareth J. Morgan2,**, Hartmut Goldschmidt3,11,**, Kari Hemminki4,5,**,
Bjo¨rn Nilsson6,17,30,** & Richard S. Houlston1,**
Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-
wide association studies have transformed our understanding of MM predisposition, but individual
studies have had limited power to discover risk loci. Here we perform a meta-analysis of these
GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188
controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995,
P¼ 1.31 10 8), 6q21 (rs9372120, P¼9.09 10 15), 7q36.1 (rs7781265, P¼9.71 10 9),
8q24.21 (rs1948915, P¼4.20 10 11), 9p21.3 (rs2811710, P¼ 1.72 10 13), 10p12.1
(rs2790457, P¼ 1.77 10 8), 16q23.1 (rs7193541, P¼ 5.00 10 12) and 20q13.13 (rs6066835,
P¼ 1.36 10 13), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC,
RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and
insight into the biological basis of tumour development.
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M
ultiple myeloma (MM) is a malignancy of plasma cells
that has a significant genetic component as evidenced
by the two- to fourfold increased risk shown in relatives
of MM patients1. Our understanding of MM susceptibility has
been transformed by recent genome-wide association studies
(GWASs), which have identified the first risk alleles for MM2–5
and its precursor condition monoclonal gammopathy of
unknown significance5. Although projections indicate that
additional risk variants for MM can be discovered by GWAS6,
the statistical power of these individual studies is limited.
To gain comprehensive insight into MM predisposition, we
performed a meta-analysis of these GWAS, new GWAS and
replication comprising 9,866 cases and 239,188 controls. We
confirmed all nine known risk loci and discovered eight new risk
loci for MM. Our findings provide further insights into the
genetic and biological basis of MM predisposition.
Results
Association analysis. To identify new MM susceptibility loci, we
analysed genome-wide association data from six populations of
European ancestry (Supplementary Tables 1 and 2): a new sample
set from the Netherlands, two previously reported sample sets
from United Kingdom and Germany, to which we added addi-
tional cases2, and three previously published sample sets from
Sweden/Norway, Iceland and the Unites States5,7. After filtering,
the six studies provided single-nucleotide polymorphism (SNP)
microarray genotypes on 7,319 cases and 234,385 controls
(Supplementary Tables 1 and 2). To increase genomic
resolution, we imputed 410 million SNPs using either the
1,000 Genomes Project8 combined with UK10K9 (MM data sets
from the Netherlands, United Kingdom, Germany, Sweden/
Norway and the United States) or deCODE Genetics (MM data
set from Iceland10) as reference. Quantile–quantile plots for SNPs
with minor allele frequency (MAF)40.5% post imputation did
not show evidence of substantive overdispersion (l¼ 1.00–1.06;
Supplementary Fig. 1). Pooling association testing results from
the six sample sets, we derived joint odds ratios and 95%
confidence intervals under a fixed-effects model for each SNP and
associated per allele P-value. In this analysis, associations for all
nine established risk loci showed a consistent direction of effect
with previously reported studies and have Po5.0 10 8 (Fig. 1
and Supplementary Table 3).
We identified 315 SNPs at 16 loci that showed evidence of
association (Po1.0 10 6) not previously implicated in the risk of
developing MM (Fig. 1 and Supplementary Tables 4 and 5). For 13 of
the 16 loci, the strongest signal was provided by an imputed SNP. We
confirmed the fidelity of imputation for 12 of the 13 imputed SNPs in
multiple series (Supplementary Tables 6 and 7; rs78311596
imputation unconfirmed). Using allele-specific PCR, we genotyped
the 15 substantiated SNPs in additional UK, Germany, Sweden/
Norway and Denmark sample series totalling 2,547 cases and 4,803
controls. Meta-analysing the discovery and replication samples, we
identified genome-wide significant associations for MM with eight
previously unreported loci (Table 1 and Supplementary Tables 8 and
9) at 6p22.3 (rs34229995, P¼ 1.31 10 8), 6q21 (rs9372120,
P¼ 9.09 10 15), 7q36.1 (rs7781265, P¼ 9.71 10 9), 8q24.21
(rs1948915, P¼ 4.20 10 11), 9p21.3 (rs2811710, P¼ 1.72
10 13), 10p12.1 (rs2790457, P¼ 1.77 10 8), 16q23.1
(rs7193541, P¼ 5.00 10 12) and 20q13.13 (rs6066835, P¼ 1.36
 10 13). We also observed two promising associations (that is,
Po5.0 10 7) at 6q27 (rs1034447) and at 7q22.3 (rs17507636)
(Supplementary Tables 8 and 9). Conditional analysis of GWAS data
showed no evidence for additional independent signals at the loci.
The 6q21 association marked by rs9372120 (Fig. 2) maps to
intron 6 of ATG5 (Homo sapiens autophagy related 5). The
8q24.21 variant rs1948915 maps to CCAT1 (colon cancer-
associated transcript 1; Fig. 2). The same region at 8q24.21
harbours multiple independent loci with different tumour
specificities11, including the B-cell malignancies diffuse B-cell
lymphoma12, Hodgkin’s lymphoma13 and chronic lymphocytic
leukaemia14. With the possible exception of chronic lymphocytic
leukaemia, the linkage disequilibrium (LD) blocks defining these
identified cancer risk loci are distinct from the 8q24.21 MM
association signal (pairwise LD metrics r2o0.03; Supplementary
Table 10). The 9p21.3 variant rs2811710 maps to intron 1 of
CDKN2A/p16INK4A (cyclin-dependent kinase inhibitor 2A,
Fig. 2). Although the 9p21.3 region is a susceptibility locus for
multiple tumour types including breast and lung cancer, glioma
and acute lymphoblastic leukaemia15, the rs2811710 association
for MM is distinct (Supplementary Table 11). The 16q23.1
(rs7193541) association is a non-synonymous SNP I564V of
RFWD3 (encoding ring finger WD domain 3; Fig. 2). 6p22.3
(rs34229995) and 7q36.1 (rs7781265) associations mark
chromatin-regulating genes; rs34229995 is 2.2-kb telomeric to
the 50 of JARID2 (jumonji, AT-rich interactive domain 2; Fig. 2)
and rs7781265 localizing to intron 2 of SMARCD3 (swi/snf-
related, matrix-associated, actin-dependent regulator of
chromatin, subfamily d, member 3; Fig. 2). The 10p12.1
(rs2790457) association localizes to intron 3 of the gene
encoding WAC (ww domain-containing adaptor with coiled-
coil region), which has recently been shown to be part of an
extended autophagy network16. The 20q13.13 (rs6066835)
association mapped to intron 3 of PREX1 (phosphatidylinositol-
3, 4, 5-trisphosphate-dependent Rac exchange factor 1) (Fig. 2).
Relationship between the new MM SNPs and phenotype. We
tested for associations between sex or age at diagnosis and
genotype for each of the eight risk SNPs by case-only analysis
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Figure 1 | Manhattan plot of association P-values. Shown are the genome-wide P-values (two sided) of 12.4 million successfully imputed autosomal SNPs
in 7,319 cases and 234,385 controls from the discovery phase. Labelled in blue are previously identified risk loci and labelled in red are newly identified risk
loci. The red horizontal line represents the genome-wide significance threshold of P¼ 5.0 10 8 and the blue horizontal line represents the threshold of
P¼ 1.0 106 used to define promising SNPs.
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using all individuals in five of the six sample sets and observed no
such relationships (Supplementary Tables 12 and 13). In addition,
case-only analysis provided no evidence for associations between
risk SNPs and cytogenetic MM subtype (Supplementary Table 14)
or MM-specific overall survival (Supplementary Table 15). Col-
lectively, these data are compatible with the risk variants having
generic effects on MM development rather than tumour
progression.
Biological inference. To the extent that they have been deci-
phered, many of the GWAS loci map to non-coding regions of
the genome and influence gene regulation. In this respect, it is
perhaps not surprising that none of the genes annotated by the
GWAS signals we identify are somatically mutated in MM
(Supplementary Table 16). Hence, to gain insight into the bio-
logical mechanisms for the associations at the eight newly iden-
tified risk SNPs, we first performed expression quantitative trait
loci (eQTL) analysis using gene expression profiles of CD138-
positive MM plasma cells from the United Kingdom (n¼ 183),
Germany (n¼ 658) and the United States (n¼ 608) cases
(Affymetrix Human Genome U133 2.0 Plus Array; NCBI GEO
Data sets GSE21349, GSE31161, GSE2658 and EBI ArrayExpress
E-MTAB-2299). In addition, we interrogated publicly accessible
expression data on whole blood, adipocytes, skin cells and lym-
phoblastoid cell lines (LCLs). To explore methylation QTL
(meQTLs) at each risk locus, we analysed Illumina Infinium
HumanMethylation450 BeadChip data on CD138-positive MM
plasma cells from 365 UK patients. In MM plasma cells, we
identified significant associations between rs2790457 and
decreased expression of WAC (P¼ 6.58 10 24) and rs6066835,
and increased expression of PREX1 (P¼ 3.85 10 5)
(Supplementary Fig. 2 and Supplementary Data 1). We also
detected strong cis-meQTLs at WAC and PREX1 with rs2790457
and rs6066835 genotypes (P-values 1.42 10 6 and
1.12 10 4, respectively; Supplementary Data 1). The direction
of these eQTLs and meQTLs is compatible with the 10p12.1
signal encompassing an active promotor for WAC, whereas the
20q13.13 signal does not capture an active promotor in the gene
body of PREX1 (Fig. 2).
DNA methylation plays a central role in epigenetic regulation
of gene expression; however, meQTLs and cis-acting eQTLs do
Table 1 | Summary results for SNPs associated with multiple myeloma risk.
Location SNP Position (bp) Risk allele RAF Data set OR P-value
6p22.3 rs34229995 15,244,018 G 0.029 Discovery 1.40 1.76 10 8
Replication 1.19 0.214
Combined 1.37 1.31 108
Phet¼0.50 I2¼0%
6q21 rs9372120 106,667,535 G 0.218 Discovery 1.20 8.72 10 14
Replication 1.12 0.0147
Combined 1.18 9.09 10 15
Phet¼0.93 I2¼0%
7q36.1 rs7781265 150,950,940 T 0.125 Discovery 1.20 1.82 10 7
Replication 1.15 0.0136
Combined 1.19 9.71 109
Phet¼0.24 I2¼ 23%
8q24.21 rs1948915 128,222,421 C 0.345 Discovery 1.14 3.14 10 10
Replication 1.09 0.0283
Combined 1.13 4.20 10 11
Phet¼0.34 I2¼ 11%
9p21.3 rs2811710 21,991,923 G 0.657 Discovery 1.14 6.50 10 10
Replication 1.18 4.02 10 5
Combined 1.15 1.72 10 13
Phet¼0.97 I2¼0%
10p12.1 rs2790457 28,856,819 G 0.739 Discovery 1.12 8.44 10 7
Replication 1.13 6.18 10 3
Combined 1.12 1.77 108
Phet¼0.94 I2¼0%
16q23.1 rs7193541 74,664,743 T 0.585 Discovery 1.12 1.14 10 8
Replication 1.17 4.79 104
Combined 1.13 5.00 10 12
Phet¼0.15 I2¼ 35%
20q13.13 rs6066835 47,355,009 C 0.083 Discovery 1.24 1.16 109
Replication 1.35 1.36 10 5
Combined 1.26 1.36 10 13
Phet¼0.072 I2¼43%
I2, proportion of the total variation due to heterogeneity; OR, odds ratio; Phet, P-value for heterogeneity; RAF, risk allele frequency; SNP, single-nucleotide polymorphism.
RAF is risk allele frequency across all cases and controls in the discovery set, where the risk allele is the allele corresponding to the estimated OR. Positions are based on NCBI build 37 of the human
genome.
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not always overlap. Thus, although rs7193541 showed a strong
meQTL for RFWD3 methylation and reduced expression of
RFWD3 in whole blood, no eQTL was shown in MM plasma cells
(Supplementary Data 1).
Various lines of evidence indicate that chromatin lopping
interactions formed between enhancer elements and genes that
they regulate map within distinct chromosomal topological
associating domains (TADs)17. To map candidate causal SNPs
to TADs and identify patterns of local chromatin patterns, we
analysed Hi-C data on the LCL cell line GM12878 (ref. 17), as a
source of B-cell information (Supplementary Fig. 3). Looping
chromatin interactions and TADs were shown at 6q21
(rs9372120), 8q24.21 (rs1948915), 9p21.3 (rs2811710) and
20q13.13 (rs6066835), involving a number of genes with
biological relevance to MM development. With the limitations
of cell line data from LCL, which may not fully reflect MM
biology, we demonstrated with MM RNA-sequencing data that
gene expression within the 6q21 and 9p21.3 TADs were tightly
correlated (Po2.0 10 5), which is consistent with their co-
regulation (Supplementary Table 17). Moreover, the region at
6q21 (rs9372120, ATG5) participates in intra-chromosome
looping with the transcriptional repressor PRDM1
(Supplementary Fig. 3b). Similarly, the 8q24.21 region of
association defined by rs1948915, which contains CCAT1
(colon cancer-associated transcript 1), interacts with MYC and
distal upstream enhancer elements (Supplementary Fig. 3d).
To explore the epigenetic profile of association signals at each
of the new MM risk loci, we used HaploReg and RegulomeDB to
examine whether the sentinel SNPs and those in high LD (that is,
r240.8 in the 1,000 Genomes EUR reference panel) annotate
putative transcription factor (TF) binding or enhancer elements.
We also assessed B-cell-specific chromatin dynamics using
FANTOM5, which uses the pre-computed chromatin state data
for multiple cell lines. HaploReg showed that the majority of
MM-related SNPs were observed in regions of DNase hypersen-
sitivity common across multiple cell lines. The protein motifs at
these sites are for known TFs such as nuclear factor-kB, c-MYC,
GATA, TCF4, POL24H8, CEBPB or POL2 (Supplementary Data
2). We examined for statistical evidence of enrichment in specific
TF binding across the eight new and nine established risk loci
using GM12878 data18. Although of borderline significance and
hypothesis generating, after correction for the 90 TFs assayed,
there was evidence for enrichment of SPI1 (alias PU.1),
(P¼ 0.0007, Padjusted¼ 0.063), which regulates PRDM1 and its
downregulation is required for MM cell growth19. Collectively, these
observations are compatible with the identified risk SNPs mapping
within regions of active chromatin state, which have a role in the
B-cell cis-regulatory network.
Discussion
We have performed the largest GWAS of MM to date. We
identified eight novel MM risk loci taking the total count to 17.
Fully deciphering the functional impact of these SNP associations
on MM development requires additional analyses. However,
seven of the SNPs map intragenic to transcribed genes, which are
relevant to MM or B-cell biology. Although a number of SNPs
displayed an eQTL/meQTL in MM plasma cells, the absence of a
relationship does not preclude the possibility of a subtle
cumulative long-term relationship intrinsic to plasma cells or a
predisposition through altered gene function in other cell types.
Studies in other cancers have shown that the multiple risk loci
at 8q24.21 are enhancers interacting with MYC20,21. As
deregulation of MYC is a feature of MM, it is plausible that the
susceptibility to MM has a similar mechanistic basis. Indeed,
MYC promotes CCAT1 transcription by binding to its promoter,
and in colorectal cancer the L-isoform of CCAT1 has been shown
to interact with the MYC promoter and distal upstream enhancer
elements regulating MYC transcription22. We have previously
shown the MM risk SNP at 7p15.3 influences expression of
CDCA7L, a binding partner of p75 potentiating MYC-mediated
transformation. In addition to local interactions with CDKN2A/
CDKN2B, the 9p21.3 region encompassing SNP rs2811710
interacts with the genomic region containing MTAP
(methylthioadenosine phosphorylase). MTAP plays a major role
in polyamine metabolism and deletion of MTAP is common in
cancer, being closely linked to homozygous deletion of p16 (ref. 23).
ATG5 at 6q21 is highly expressed in plasma cells and essential
for autophagy and plasma cell survival24. Strikingly, the same
locus also contains the transcriptional repressor PRDM1
(formerly BLIMP1), which is key to the development of plasma
cells from B cells and a determinant of plasma cell survival25. The
RFWD3 protein is an E3 ubiquitin ligase that positively regulates
p53 stability by forming an RFWD3–MDM2–p53 complex,
thereby protecting p53 from degradation by MDM2-mediated
polyubiquitination26. Variation at 16q23.1 defined with the
correlated SNP rs4888262 (pairwise LD with rs7193541,
r2¼ 0.68, D’¼ 1.0) has previously been shown to influence
testicular cancer risk27, suggesting a common genetic and
biological basis to both associations.
JARID2 functions as a transcriptional repressor through
recruitment of Polycomb repressive complex 2 and has recently
been identified as a regulator of haematopoietic stem cell
function28, and the 6p22.3-p21.31 region is commonly gained
in MM tumours29. Inhibition of JARID2 leads to loss of
Polycomb binding and a reduction of histone H3 lysine-27
trimethylation levels on target genes. SMARCD3 recruits BAF
chromatin remodelling complexes to specific enhancers.
Although there is currently no evidence to implicate the
transcriptional repressors JARID2 or SMARCD3 in terms of
somatic mutation in MM, multiple genes including CDKN2A and
TP53 are silenced by methylation in MM. Overexpression of
histone methyltransferase and inactivating mutations in histone
demethylase (UTX) typifies a subset of MM30 and our findings
add to the impact of chromatin remodelling genes on MM.
We have previously shown an association for MM at ULK4, a
key regulator of mammalian target of rapamycin-mediated
autophagy4. We now suggest a more extensive set of
associations involving ATG5 and WAC, and by virtue of the
role of MYC in autophagy31, CCAT1, CDCA7L, DNMT3A and
CBX7. Collectively, these data invoke deregulation of DNA
methylation, telomere length, differentiation and autophagy,
and immunoglobulin production as determinants of MM
susceptibility.
Our findings provide further evidence for an inherited genetic
susceptibility to MM. However, further studies are necessary to
understand the biology behind these risk variants. We estimate
that the currently identified risk SNPs for MM account for 20% of
the heritable risk attributable to all common variation; hence,
further GWAS-based studies in concert with functional analyses
should lead to additional insights into MM biology. Importantly,
such studies may inform the development of new therapeutic
agents32,33.
Methods
Ethics. Collection of patient samples and associated clinico-pathological infor-
mation was undertaken with written informed consent and relevant ethical review
board approval at respective study centres in accordance with the tenets of the
Declaration of Helsinki, specifically for the Myeloma-IX trial by the Medical
Research Council (MRC) Leukaemia Data Monitoring and Ethics committee
(MREC 02/8/95, ISRCTN68454111), the Myeloma-XI trial by the Oxfordshire
Research Ethics Committee (MREC 17/09/09, ISRCTN49407852), HOVON65/
GMMG-HD4 (ISRCTN 644552890; METC 13/01/2015), HOVON87/NMSG18
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12050 ARTICLE
NATURE COMMUNICATIONS | 7:12050 |DOI: 10.1038/ncomms12050 |www.nature.com/naturecommunications 5
(EudraCTnr 2007-004007-34, METC 20/11/2008), HOVON95/EMN02
(EudraCTnr 2009-017903-28, METC 04/11/10), University of Heidelberg Ethical
Commission (229/2003, S-337/2009, AFmu-119/2010), University of Arkansas for
Medical Sciences Institutional Review Board (IRB 202077), Lund University Ethical
Review Board (2013/54) and Icelandic Data Protection Authority (2,001,010,157
and National Bioethics Committee 01/015).
Genome-wide association studies. The diagnosis of MM (ICD-10 C90.0) was
established in accordance with World Health Organization guidelines. All samples
from patients for genotyping were obtained before treatment or at presentation.
The meta-analysis was based on GWAS conducted in the Netherlands, the United
Kingdom, Germany, Sweden/Norway, the United States and Iceland
(Supplementary Tables 1 and 2).
The Dutch GWAS consisted of 608 cases (316 male). The cases were ascertained
from three clinical trials: HOVON65/GMMG-HD4 ISRCTN64455289 (restricted
to Dutch cases; n¼ 158), HOVON87/NMSG18 (n¼ 292) and HOVON95/EMN02
(n¼ 105) (ISRCTN64455289: GMMG-HD4 http://www.isrctn.com/
search?q=ISRCTN64455289, HOVON87/NMSG18; HOVON87/NMSG18 https://
www.clinicaltrialsregister.eu/ctr-search/trial/2007-004007-34/BE and HOVON95/
EMN02 https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-017903-28/AT).
DNA was extracted from venous blood samples and genotyped using Illumina
Human OmniExpress-12 v1.0 arrays (Illumina, San Diego, USA). For controls, we
used the B-PROOF data set (B-vitamins for the prevention of osteoporotic
fractures). Controls were genotyped using Illumina OmniEpress Exome-8v1-1
arrays34.
The UK GWAS2 comprised 2,329 cases (1,060 male (post quality control (QC));
mean age at diagnosis: 64 years) recruited through the UK MRC Myeloma-IX and
Myeloma-XI trials (ISRCTN68454111: Myeloma IX http://www.isrctn.com/
search?q=ISRCTN68454111 and ISRCTN49407852: Myeloma XI http://
www.isrctn.com/search?q=ISRCTN49407852). DNA was extracted from EDTA-
venous blood samples (90% before chemotherapy) and genotyped using Illumina
Human OmniExpress-12 v1.0 arrays (Illumina). For controls, we used publicly
accessible data generated by the Wellcome Trust Case Control Consortium from
the 1958 Birth Cohort (58C; also known as the National Child Development Study)
and National Blood Service. Genotyping of controls was conducted using Illumina
Human 1-2M-Duo Custon_v1 Array chips (www.wtccc.org.uk).
The German GWAS2 comprised 1,512 cases (867 male (post QC); mean age at
diagnosis: 59 years) recruited by the German-Speaking Multiple Myeloma
Multicenter Study Group (GMMG) coordinated by the University Clinic,
Heidelberg (ISRCTN06413384: GMMG-HD3 http://www.isrctn.com/
search?q=ISRCTN06413384; ISRCTN64455289: GMMG-HD4 http://
www.isrctn.com/search?q=ISRCTN64455289; and ISRCTN05745813: GMMG-
HD5 http://www.isrctn.com/search?q=ISRCTN05745813). DNA was prepared
from EDTA-venous blood or CD138-negative bone marrow cells (o1% tumour
contamination). Genotyping was performed using Illumina Human OmniExpress-
12 v1.0 arrays (Illumina). For controls, we used genotype data on 2,107 healthy
individuals, enroled into the Heinz Nixdorf Recall (HNR) study genotyped using
either Illumina HumanOmni1-Quad_v1 or 1428 OmniExpress-12 v1.0 arrays.
The Swedish/Norwegian GWAS5 was based on 1,668 and 157 MM patients
from the Swedish National Myeloma Biobank (Skåne University Hospital, Lund,
Sweden) and the Norwegian Biobank for Myeloma (Trondheim, Norway),
respectively. Genotyping was performed using Illumina Human OmniExpress-
Exome arrays (Illumina). Control genotypes on 10,704 individuals were obtained
from previously published studies of schizophrenia and TWINGENE5.
The USA GWAS7 comprised 1,076 newly diagnosed patients treated at the
UAMS Myeloma Institute for Research and Therapy (NCT00083551: Total therapy
II https://clinicaltrials.gov/ct2/show/NCT00083551; NCT00081939: Total therapy
III https://clinicaltrials.gov/ct2/show/NCT00081939; NCT00572169: Total therapy
3B https://clinicaltrials.gov/ct2/show/NCT00572169; and NCT00734877: Total
therapy 4 https://clinicaltrials.gov/ct2/show/NCT00734877). DNA was isolated
from peripheral blood samples collected from patients after granulocyte–colony-
stimulating factor mobilization of stem cells. Genotyping was performed using
Illumina Human OmniExpress-12 v1.0 arrays and OmniExpress arrays
(Illumina)7. Genotype data from 2,234 healthy individuals enroled into the Cancer
Genetic Markers of Susceptibility studies served as a source of controls.
The Icelandic GWAS comprised 480 MM cases identified from the nationwide
Icelandic Cancer Registry5. Samples were genotyped using Illumina microarrays5.
Analysis of GWAS. The Swedish/Norwegian GWAS has been previously pub-
lished in its entirety with a full description of QC5. Adopting the same standard,
quality-control measures were applied to the UK, German, US and the Netherlands
GWAS. Specifically, we excluded individuals with low call rate (o95%) and those
found to have non-European ancestry on the basis of HapMap version 2 CEU, JPT/
CHB and YRI population reference data (Supplementary Fig. 4). For first-degree
relative pairs, we excluded the control or the individual with the lower call rate.
SNPs with a call rate o95% were excluded as were those with a MAFo0.01 or
displaying significant deviation from Hardy–Weinberg equilibrium (that is,
Po10 5). Post QC, the 5 GWAS provided genotype data on 6,839 cases and
22,221 controls. GWAS data were imputed for all scans for 410 million SNPs
using 1,000 Genomes Project (phase 1 integrated release 3, March 2012)8 and
UK10K data (ALSAPAC, EGAS00001000090/EGAD00001000195 and TwinsUK
EGAS00001000108/EGAS00001000194 studies only)9 as reference in conjunction
with IMPUTE2 v2.3 software35 (Supplementary Tables 1 and 2). Imputation was
conducted separately for each scan and each GWAS was pruned to a common set
of SNPs between cases and controls. We pre-set thresholds for imputation quality,
to retain potential risk variants with MAF40.005 for validation. Specifically, we
excluded poorly imputed SNPs (that is, information measure Is o0.80). Test of
association between imputed SNPs and MM was performed using logistic
regression using SNPTESTv2.5.2 (ref. 36). The adequacy of the case–control
matching was formally evaluated using quantile–quantile plots of test statistics
(Supplementary Fig. 1). The inflation factor l was based on the 90% least-
significant SNPs37. Where appropriate, principle components (zero for UK, five for
Sweden/Norway, two for Germany, zero for USA and zero for the Netherlands),
generated using common SNPs, were included to limit the effects of cryptic
population stratification. Eigenvectors for the GWAS data sets were inferred using
smartpca (part of EIGENSOFT38) by merging cases and controls with Phase II
HapMap samples.
For the Icelandic GWAS, SNP genotypes were phased using a long-range
method based on whole genome sequence data on 2,636 Icelanders. Sequence
variants (35.5 million) were then imputed into 104,220 Icelanders, which had been
genotyped using Illumina chips. We corrected for familial relatedness by genomic
control dividing the w2-statistic by 1.04.
Meta-analysis. We performed association testing in the discovery sets separately
and then combined the results for 12.4 million variants. We assessed the fidelity of
imputation through the concordance between imputed and directly genotyped
SNPs in a subset of GWAS samples (Supplementary Tables 6 and 7). Meta-analysis
was undertaken using the inverse-variance approach under a fixed-effects model
implemented in META v1.6 (ref. 39). Cochran’s Q-statistic was calculated, to test
for heterogeneity, and the I2 statistic measured, to quantify the proportion of the
total variation due to heterogeneity40. Meta-analysis summary statistics and LD
correlations from a reference panel of 1,000 Genomes Project combined with
UK10K, we used GCTA41 to perform conditional association analysis. Association
statistics were calculated for all SNPs conditioning on the top SNP in each loci
showing genome-wide significance. This is performed in a step-wise manner.
Replication genotyping. To validate promising associations, we analysed four
case–control series from the United Kingdom, Germany, Denmark and Sweden/
Norway.
The UK replication comprised 812 MM cases (412 male) ascertained through the
UK MRC Myeloma-IX (n¼ 95) and XI trials (n¼ 717). Controls comprised 1,110
healthy individuals with self-reported European ancestry (420 male, aged 18–69
years) with no personal history of malignancy ascertained through GEnetic Lung
CAncer Predisposition Study (n¼ 536) (ref. 42) and National Study of Colorectal
Cancer Genetics (n¼ 574) (ref. 43). All cases and controls were UK residents.
The German replication series comprised 1,149 cases collected by the German
Myeloma Study Group (Deutsche Studiengruppe Multiples Myelom (DSMM)),
GMMG, University Clinic, Heidelberg, and University Clinic, Ulm (676 male,
mean age at diagnosis 57.6 years, s.d. 9.8). Controls comprised of 1,582 healthy
German blood donors recruited between 2004 and 2007 by the Institute of
Transfusion Medicine and Immunology, University of Mannheim, Germany (885
male, mean age 55.8 years, s.d. 10.0).
The Swedish/Norway and Danish replication series comprised 223 MM cases
from the Swedish National Myeloma Biobank and 363 MM cases from the
University Hospital of Copenhagen. As controls for these respective replication
sets, we analysed 1,285 Swedish blood donors and 826 individuals from Denmark
and Skåne County, Sweden (the southernmost part of Sweden adjacent to
Denmark).
Replication genotyping was performed using allele-specific PCR KASPar
chemistry (LGC, Hertfordshire, UK; UK replication series). Primers, probes and
conditions used are available on request. Call rates for SNP genotypes were495%
in each of the replication series. The quality of genotyping in all assays was assessed
by measuring 1–10% duplicates (showing a concordance of499%) and at least two
negative controls for each centre. Technical artefacts were excluded by cross-
platform validation of 96 samples and sequencing of a set of 96 randomly selected
samples from each case and control series confirmed genotyping accuracy.
Concordance of 499% demonstrated robust performance.
Translocation detection and mutation analysis. Karotyping was used for cyto-
genetic studies of MM cells and standard criteria for the definition of a clone were
applied. Fluorescence in situ hybridization and ploidy classification of UK samples
was conducted using the methodologies previously described44. Fluorescence
in situ hybridization and ploidy classification of German samples was performed as
previously described45. The XL IGH Break Apart probe (MetaSystems, Altlussheim
Germany) was used to detect any IGH translocation in German samples. Logistic
regression in case-only analyses was used to assess tumour karyotype . The
frequency of somatic mutation in genes annotated by GWAS signals was derived
from tumour whole-exome sequencing of 463 Myeloma XI trial patients46.
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Association between genotype and patient outcome. To examine the rela-
tionship between SNP genotype and patient outcome, we analysed GWAS data on
four of the patient cohorts2–4,7, specifically (i) 1,165 cases from the UK MRC
Myeloma-IX trial (UK-GWAS); (ii) 877 MM cases from the UK MRC Myeloma-XI
trial (UK-GWAS); (iii) 511 of the patients recruited to the German GWAS; and (iv)
703 MM cases in the UAMS Myeloma Institute for Research and Therapy GWAS
(USA GWAS)7. Clinical trial information on these patients has been previously
reported47–50. The primary analysis end point was myeloma-specific overall
survival and analysis was performed as previously described51. Cox regression
analysis was used to derive genotype-specific hazard ratio and associated 95%
confidence intervals. Meta-analysis was performed under a fixed-effects model
(Supplementary Table 15).
eQTL analysis. We performed an eQTL analyses using Affymetrix Human
Genome U133 2.0 Plus Array data for plasma cells from 183 MRC Myeloma IX
trial patients29, 658 Heidelberg patients and 608 US patients as recently described.
Briefly, GER, UK and US data were separately pre-processed and analysed using a
Bayesian approach to probabilistic estimation of expression residuals to infer broad
variance components, thus accounting for hidden determinants influencing global
expression such as copy number, translocation status and batch effects52. The
association between genotype of the sentinel variant and gene expression of genes
within 500 Kb either side was evaluated based on the significance of linear
regression coefficients. We pooled data from each study under a fixed-effects model
controlling for false discovery rate (FDR) calling significant associations with a
FDRr0.05. In addition, we queried publicly available eQTL messenger RNA
expression data using MuTHER and the Blood eQTL browser. MuTHER contains
expression data on LCLs, skin and adipose tissue from 856 healthy twins53. The
Blood eQTL browser contains expression data from 5,311 non-transformed
peripheral blood samples54.
meQTL analysis. We performed cis-meQTL analysis using Illumina 450K
methylation array data on plasma cells from 384 MRC Myeloma XI trial patients.
As with analysis of MM expression (eQTL) data, we inferred hidden determinants
influencing global methylation. The genetic association was tested under an
additive model between each SNP and each normalized methylation probe,
adjusting for plate and methylation-based principal component analysis score.
Controlling for a FDR of 0.05 across the 338,456 methylation traits required a
P-value for association to be o4.0 10 5.
ENCODE and chromatin state dynamics. Risk SNPs and their proxies (that is,
r240.8 in the 1,000 Genomes EUR reference panel) were annotated for putative
functional effect using HaploReg v3 (ref. 55), RegulomeDB56 and SeattleSeq57
annotation. These servers make use of data from ENCODE58, genomic
evolutionary rate profiling59 conservation metrics, combined annotation dependent
depletion scores60 and PolyPhen scores61. We examined for an overlap of
associated SNPs with predicted enhancers using the FANTOM5 enhancer
atlas62and searched for overlap with ‘super-enhancer’ regions using data from
Hnisz et al.63, restricting our analysis to GM12878.
To formally examine for enrichment in specific TF binding across risk loci, we
adopted the method of Gaulton et al.18 Briefly, for each risk locus we derived a
credible set of SNPs with a 99% probability of containing the causal SNP; posterior
probability for each SNP being computed from its Bayes factor. SNPs were ranked
by their posterior probability and included so that the cumulative posterior
probability for association was 40.99. Binding sites for 90 TF in GM12878 were
obtained from ENCODE. For each TF the total posterior probability over all
credible set SNPs overlapping all binding sites was calculated. A null distribution
was generated by randomly relocating each binding site up to 100 kb from its
original location. For these perturbed sites, the total posterior probability over all
overlapping SNPs was calculated. This process was repeated 10,000 times and
enrichment P-values calculated as the fraction of permutations where the total
posterior probability was greater than for the unperturbed binding sites.
Hi-C data and definition of topological domains at risk loci. Hi-C data was used
to map the candidate causal SNPs to chromosomal TADs and identify patterns of
relevant, local chromatin interactions. We made use of publicly available raw Hi-C
data on GM12878 cells17. Valid Hi-C pairs were generated aligning raw reads to
the reference genome using Burrows-Wheeler alignment (BWA), matching pairs of
reads and filtering for biases. Bona fide Hi-C ditags were allocated to a contact
matrix, with a predefined, uniform resolution of 5 kb. We corrected for
experimental bias using the matrix balancing approach64. We inferred TADs from
the contact matrix by means of the arrowhead algorithm for domain detection as
previously proposed.
To investigate whether genes within TADs are co-regulated, we obtained
RNAseq transcript counts from 66 MM cell lines from the Keat’s lab Data
Repository (http://www.keatslab.org/data-repository)65. We performed pairwise
correlation by calculating the Pearson’s product–moment correlation coefficient of
the transcript counts for all pairs of genes within respective TADs.
Heritability analysis. We used Genome-wide Complex Trait Analysis to estimate
the polygenic variance ascribable to all genotyped and imputed GWAS SNPs
simultaneously for the UK and German GWAS41,66,67. SNPs were excluded based
on low MAF, poor imputation and poor HWE. Principal components were
included as covariates in the heritability analysis of the German data. As previously
advocated when calculating the heritability of a disease such as cancer we used the
lifetime risk68,69, which for MM is estimated to be 0.007 for the UK population
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/
incidence/uk-multiple-myeloma-incidence-statistics#Lifetime) and 0.006 for the
German population. We estimated the heritability explained by risk SNPs
identified by GWAS as located within regions associated with MM. Meta-analysis
of heritability estimates from UK and German GWAS data sets was performed
under a standard fixed-effects model.
Data availability. SNP genotyping data that support the findings of this study
have been deposited in Gene Expression Omnibus with accession codes GSE21349,
GSE19784, GSE24080, GSE2658 and GSE15695; in the European Genome-phe-
nome Archive (EGA) with accession code EGAS00000000001; in the European
Bioinformatics Institute (Part of the European Molecular Biology Laboratory)
(EMBL-EBI) with accession code E-MTAB-362 and E-TABM-1138; and in the
database of Genotypes and Phenotypes (dbGaP) with accession code
phs000207.v1.p1.
Expression data that support the findings of this study have been deposited in
GEO with accession codes GSE21349, GSE2658, GSE31161 and EMBL-EBI with
accession code E-MTAB-2299.
Whole-exome sequence data that support the findings of this study have been
deposited in EGA with accession code EGAS00001001147.
Transcription profiling data from MuTHer studies that support the findings of
this study have been deposited in EMBL-EBI with accession code E-TABM-1140.
Data from Blood eQTL have been deposited in EMBL-EBI with accession codes
E-TABM-1036, E-MTAB-945 and E-MTAB-1708.
The remaining data are contained within the paper and Supplementary Files or
available from the author upon request.
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